Screener
Gilead Sciences GILD Intangibles (Net)
Intangibles (Net) at other companies
Other financials
Where this comes from
Reported directly by Gilead Sciences in its filing.
Tagged under the XBRL concept us-gaap:FiniteLivedIntangibleAssetsNet.
The source filing: Gilead Sciences’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:13 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000882095-26-000031
| (in millions) | June 30, 2026 / Gross Carrying Amount | June 30, 2026 / Accumulated Amortization | June 30, 2026 / Foreign Currency Translation Adjustment | June 30, 2026 / Net Carrying Amount | December 31, 2025 / Gross Carrying Amount | December 31, 2025 / Accumulated Amortization | December 31, 2025 / Foreign Currency Translation Adjustment | December 31, 2025 / Net Carrying Amount |
|---|---|---|---|---|---|---|---|---|
| Intangible asset – sofosbuvir | $10,720 | $(8,797) | — | $1,923 | $10,720 | $(8,448) | — | $2,272 |
| Intangible asset – axicabtagene ciloleucel | 7,110 | (3,330) | — | 3,780 | 7,110 | (3,127) | — | 3,983 |
| Intangible asset – Trodelvy | 11,730 | (4,704) | — | 7,026 | 11,730 | (4,164) | — | 7,566 |
| Intangible asset – Hepcludex(1) | 1,395 | (462) | — | 933 | 845 | (415) | — | 430 |
| Other | 1,458 | (1,087) | — | 372 | 1,483 | (1,056) | — | 428 |
| Total finite-lived assets | 32,413 | (18,382) | — | 14,032 | 31,888 | (17,211) | — | 14,678 |
| Indefinite-lived assets – IPR&D(1)(2) | — | — | — | — | 2,300 | — | — | 2,300 |
| Total intangible assets | $32,413 | $(18,382) | — | $14,032 | $34,188 | $(17,211) | — | $16,978 |
Item 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FAQ
- What is Gilead Sciences's intangibles (net)?
- Gilead Sciences (GILD) reported intangibles (net) of $14.03B in Q2 2026.
- How has Gilead Sciences's intangibles (net) changed year-over-year?
- Gilead Sciences's intangibles (net) decreased by 11.6% year-over-year, from $15.87B to $14.03B.
- What is the long-term trend for Gilead Sciences's intangibles (net)?
- Over 5 years (2020 to 2025), Gilead Sciences's intangibles (net) has grown at a -15.0% compound annual growth rate (CAGR), from $33.13B to $14.68B.
- What does intangibles (net) mean?
- Identifiable intangible assets (patents, trademarks, customer relationships, technology) net of accumulated amortization — excluding goodwill.
Ask your AI about Gilead Sciences's intangibles (net).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude